Generic Injectables Market By Product Type (Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Blood Factors, Immunoglobulins, Peptide Antibiotics, Vaccines, and Others), Indication (Diabetes, Cancer, Cardiovascular Diseases, Musculoskeletal, CNS, Infections, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Drug Stores, and Online Prescription Stores), and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Generic Injectables Market size was valued at USD 83.09 billion in 2022 and is expected to grow at a CAGR of 12.2% from 2023-2029. Generic injectables are bioequivalent to their branded counterparts; they are as safe and effective as innovator compounds. Only after the patent on the branded drug has expired can these medications be created for commercial use. Generic injectables have low R&D costs because the drug molecules are equivalent in branded and generic formulations. Drugmakers can sell generic injectables at low prices because of the minimal upfront R&D costs. According to the USFDA, a single generic competitor can result in price reductions of 30%, whereas five generic competitors can result in price reductions of 85%. Furthermore, generic drugs are approved faster than branded medicines. According to the US Food and Drug Administration (USFDA), 107 first-generation generic pharmaceuticals and 110 complicated generic drugs were approved in 2019, accounting for 11% of all generic drug product approvals. One thousand fourteen generic medicine applications were granted or tentatively approved by the generic drugs program in 2019. Furthermore, the development of a new chemical entity takes roughly a decade on average, whereas generic injectables are developed in a fraction of that time. As a result, one of the primary drivers encouraging new companies to enter the market and driving the generic injectables market is the lower cost associated with generic injectables. Manufacturers in the generic injectables market are preparing for the future by keeping adequate supply chains to avoid any COVID-19-like vulnerabilities. Drug companies such as Zydus Cadila have been seen lowering the price of Remdac, the generic version of Remdesivir. Companies are utilizing government programs and financing schemes given by the BFSI industry to streamline their operations in response to turbulent market conditions. Furthermore, branded injectables' patents are set to expire in the coming years in several countries, presenting a lucrative opportunity for generic injectables manufacturers. Generational injectables businesses target regulated markets and explore other markets to generate funds and build steady revenue streams.

The Generic Injectables Market Key Developments:
  • In January 2022, Hikma Pharmaceuticals launched Hikma 503B, a new outsourced sterile compounding business. The unit would focus on providing high-quality, ready-to-administer injectables and customized medications for the US market.
  • In April 2022, Hospira, Inc., the world leader in generic injectable pharmaceuticals, acquired the generic injectable pharmaceuticals business of Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, for approximately $400 Billion.

Generic Injectables Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

12.2%

Largest Market

North-America

Fastest Growing Market

Asia-Pacific
Generic Injectables Market Dynamics

As medicine shortages worsen, governments in several countries are promoting the production of generic injectables, which do not have patents. The increasing aging population and the rise in chronic disease cases are two further factors contributing to the growth of generic injectables. Since generic injectables are bioequivalent, generic medications have shorter R&D cycles than their branded counterparts, and these benefits producers by reducing time and contributing to expanding the generic injectable market. The expiration of branded injectable patents and a decrease in the frequency of new launches are two reasons that have aided the expansion of the generic injectable industry. On the other hand, the production of generic injectables is relatively complex. In many underdeveloped nations, the absence of competent labor can be a stumbling block for the generic injectable industry.

Generic Injectables Market Segmentation

By Product Type
  • Monoclonal Antibodies
  • Cytokines
  • Insulin
  • Vaccines
  • Peptide Hormones
  • Blood Factors
  • Immunoglobulins
  • Peptide Antibiotics
  • Others
By Indication
  • Diabetes
  • Cancer
  • Cardiovascular Diseases
  • Musculoskeletal
  • CNS
  • Infections
  • Others
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Drug Stores
  • Online Prescription Stores

Frequently Asked Questions

The generic injectables market is projected to expand at a CAGR of 12.2% during the forecast period.  

Novartis, AbbVie Inc., Amgen, Inc., AstraZeneca Plc, Baxter International Inc.

North America is the fastest-growing region for the generic injectables market

Key Features of the Reports

  • The generic injectables market report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1.Executive Summary
2.Global Generic Injectables Market Introduction 
2.1.Global Generic Injectables Market  - Taxonomy
2.2.Global Generic Injectables Market  - Definitions
2.2.1.Product Type
2.2.2.Indication
2.2.3.Distribution Channel
2.2.4.Region
3.Global Generic Injectables Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Generic Injectables Market Analysis, 2018-2022 and Forecast 2023-2029
4.1.  Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Generic Injectables Market  By Product Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Monoclonal Antibodies
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Cytokines
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Insulin
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Vaccines
5.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Peptide Hormones
5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
5.6. Blood Factors
5.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.6.3. Market Opportunity Analysis 
5.7. Immunoglobulins
5.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.7.3. Market Opportunity Analysis 
5.8. Peptide Antibiotics
5.8.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.8.3. Market Opportunity Analysis 
5.9. Others
5.9.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.9.3. Market Opportunity Analysis 
6.Global Generic Injectables Market  By Indication, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Diabetes
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Cancer
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Cardiovascular Diseases
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Musculoskeletal
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. CNS
6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
6.6. Infections
6.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.6.3. Market Opportunity Analysis 
6.7. Others
6.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.7.3. Market Opportunity Analysis 
7.Global Generic Injectables Market  By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Hospital Pharmacy
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacy
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Drug Stores
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Online Prescription Stores
7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
8.Global Generic Injectables Market  By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Generic Injectables Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Product Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Monoclonal Antibodies
9.1.2.Cytokines
9.1.3.Insulin
9.1.4.Vaccines
9.1.5.Peptide Hormones
9.1.6.Blood Factors
9.1.7.Immunoglobulins
9.1.8.Peptide Antibiotics
9.1.9.Others
9.2.  Indication Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Diabetes
9.2.2.Cancer
9.2.3.Cardiovascular Diseases
9.2.4.Musculoskeletal
9.2.5.CNS
9.2.6.Infections
9.2.7.Others
9.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital Pharmacy
9.3.2.Retail Pharmacy
9.3.3.Drug Stores
9.3.4.Online Prescription Stores
9.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Generic Injectables Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Monoclonal Antibodies
10.1.2.Cytokines
10.1.3.Insulin
10.1.4.Vaccines
10.1.5.Peptide Hormones
10.1.6.Blood Factors
10.1.7.Immunoglobulins
10.1.8.Peptide Antibiotics
10.1.9.Others
10.2.  Indication Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Diabetes
10.2.2.Cancer
10.2.3.Cardiovascular Diseases
10.2.4.Musculoskeletal
10.2.5.CNS
10.2.6.Infections
10.2.7.Others
10.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital Pharmacy
10.3.2.Retail Pharmacy
10.3.3.Drug Stores
10.3.4.Online Prescription Stores
10.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
10.4.7.
11.Asia Pacific (APAC) Generic Injectables Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Monoclonal Antibodies
11.1.2.Cytokines
11.1.3.Insulin
11.1.4.Vaccines
11.1.5.Peptide Hormones
11.1.6.Blood Factors
11.1.7.Immunoglobulins
11.1.8.Peptide Antibiotics
11.1.9.Others
11.2.  Indication Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Diabetes
11.2.2.Cancer
11.2.3.Cardiovascular Diseases
11.2.4.Musculoskeletal
11.2.5.CNS
11.2.6.Infections
11.2.7.Others
11.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital Pharmacy
11.3.2.Retail Pharmacy
11.3.3.Drug Stores
11.3.4.Online Prescription Stores
11.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Generic Injectables Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Monoclonal Antibodies
12.1.2.Cytokines
12.1.3.Insulin
12.1.4.Vaccines
12.1.5.Peptide Hormones
12.1.6.Blood Factors
12.1.7.Immunoglobulins
12.1.8.Peptide Antibiotics
12.1.9.Others
12.2.  Indication Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Diabetes
12.2.2.Cancer
12.2.3.Cardiovascular Diseases
12.2.4.Musculoskeletal
12.2.5.CNS
12.2.6.Infections
12.2.7.Others
12.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital Pharmacy
12.3.2.Retail Pharmacy
12.3.3.Drug Stores
12.3.4.Online Prescription Stores
12.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Generic Injectables Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
13.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Monoclonal Antibodies
13.1.2.Cytokines
13.1.3.Insulin
13.1.4.Vaccines
13.1.5.Peptide Hormones
13.1.6.Blood Factors
13.1.7.Immunoglobulins
13.1.8.Peptide Antibiotics
13.1.9.Others
13.2.  Indication Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Diabetes
13.2.2.Cancer
13.2.3.Cardiovascular Diseases
13.2.4.Musculoskeletal
13.2.5.CNS
13.2.6.Infections
13.2.7.Others
13.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital Pharmacy
13.3.2.Retail Pharmacy
13.3.3.Drug Stores
13.3.4.Online Prescription Stores
13.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.AstraZeneca
14.2.2.Baxter International, Inc.
14.2.3.Biocon
14.2.4.Fresenius SE & Co. KGaA
14.2.5.GlaxoSmithKline plc
14.2.6.Hikma Pharmaceuticals plc
14.2.7.Johnson & Johnson Services, Inc.
14.2.8.Lupin Ltd.
14.2.9.Merck KGaA
14.2.10.Mylan N.V.
14.2.11.Novartis AG (Sandoz International GmbH)
14.2.12.Pfizer, Inc.
15. Research Methodology 
16. Appendix and Abbreviations 
  • AstraZeneca
  • Baxter International, Inc.
  • Biocon
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals plc
  • Johnson & Johnson Services, Inc.
  • Lupin Ltd.
  • Merck KGaA
  • Mylan N.V.
  • Novartis AG (Sandoz International GmbH)
  • Pfizer, Inc.

Adjacent Markets